Molecular Neurobiology
https://doi.org/10.1007/s12035-020-02195-8

Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes

Dhivya Arasappan[1] · Simon B. Eickhoff[2,3] · Charles B. Nemeroff[4,5,6] · Hans A. Hofmann[7,8] · Mbemba Jabbi[4,5,7,9]

Received: 8 May 2020 / Accepted: 30 October 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract

Mood disorders represent a major cause of morbidity and mortality worldwide but the brain-related molecular pathophysiology in mood disorders remains largely undefined. Because the anterior insula is reduced in volume in patients with mood disorders, RNA was extracted from the anterior insula postmortem anterior insula of mood disorder samples and compared with unaffected controls for RNA-sequencing identification of differentially expressed genes (DEGs) in (a) bipolar disorder (BD; $n = 37$) versus (vs.) controls ($n = 33$), and (b) major depressive disorder (MDD $n = 30$) vs. controls, and (c) low vs. high axis I comorbidity (a measure of cumulative psychiatric disease burden). Given the regulatory role of transcription factors (TFs) in gene expression via specific-DNA-binding domains (motifs), we used JASPAR TF binding database to identify TF-motifs. We found that DEGs in BD vs. controls, MDD vs. controls, and high vs. low axis I comorbidity were associated with TF-motifs that are known to regulate expression of toll-like receptor genes, cellular homeostatic-control genes, and genes involved in embryonic, cellular/organ, and brain development. Robust imaging-guided transcriptomics by using meta-analytic imaging results to guide independent postmortem dissection for RNA-sequencing was applied by targeting the gray matter volume reduction in the anterior insula in mood disorders, to guide independent postmortem identification of TF motifs regulating DEG. Our findings of TF-motifs that regulate the expression of immune, cellular homeostatic-control, and developmental genes provide novel information about the hierarchical relationship between gene regulatory networks, the TFs that control them, and proximate underlying neuroanatomical phenotypes in mood disorders.

Keywords Brain · Gene expression · Transcription factors · Behavior · Mood disorders · RNA-sequencing

✉ Mbemba Jabbi
mbemba.jabbi@austin.utexas.edu

1 Center for Biomedical Research Support, University of Texas at Austin, Austin, TX, USA

2 Institute of Systems Neuroscience, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

3 Institute of Neuroscience and Medicine (INM-7), Research Centre Jülich, Jülich, Germany

4 Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA

5 The Mulva Clinic for Neurosciences, Dell Medical School, University of Texas at Austin, Austin, TX, USA

6 Institute of Early Life Adversity Research, Austin, TX, USA

7 Institute for Neuroscience, University of Texas at Austin, Austin, TX, USA

8 Department of Integrative Biology, University of Texas at Austin, Austin, TX, USA

9 Department of Psychology, University of Texas at Austin, Austin, TX, USA

Introduction

Adaptive behavior is, in part, governed by genes, especially their coding regions, through gene-mediated molecular processes that are critical for brain development and function. These gene mediated processes, through changes in gene expression, can give rise to complex behavioral phenotypes. Transcription factors (TFs) are sequence-specific DNA-binding proteins that are also known as regulatory proteins. TFs regulate the expression of genes by recognizing and binding to specific DNA regulatory elements called DNA binding domains in the promoter region of genes [1, 2]. This attribute enables TFs to hierarchically regulate the expression of genes by controlling (i.e., promoting/activating or blocking/repressing) transcription of the adjacent coding regions into mRNA, and subsequent translation into proteins [1, 2]. TFs are therefore in a functionally elevated status in the hierarchy of gene expression repertoires because they are able to cooperatively or synergistically regulate genes encoding other TFs [2]. Consequently, gene regulatory networks underlie

Published online: 07 January 2021

essential biological processes such as brain development, synaptic formations, and emergent behaviors like learning and memory that depend on neurodevelopmental processes [3, 4, 5].

Based on the complex role of thousands of transcription factors in controlling gene regulation, dysregulation of TF-mediated gene expression programs has been hypothesized to contribute to a broad range of diseases [6], including neuropsychiatric disorders ([, 6, 1, 7, 8]). However, the putative role of TF networks in mood disorder pathogenesis is not well understood. Adult brain gray matter volumetric (GMV) reductions in the anterior part of the insula, a region of the cerebral cortex folded deep within the lateral sulcus, have been consistently identified in mood disorders [9, 10]. Such reduced GMV are found to predict cognitive impairment and affective dysfunction in both MDD and BD [11]. Functional magnetic resonance imaging (fMRI) of the right anterior insula region has been reported to selectively predict the therapeutic response to psychotherapy and pharmacotherapy [12]. Because mood disorders are the most common neuropsychiatric syndromes [13], and they collectively account for a high global burden of disease [14, 15, 16], the current study examined the role of TFs in anterior insula gene expression profiles associated with affective dysfunction. Specifically, we used robust imaging-guided transcriptomics, a method that performs meta-analyses of neuroimaging results of gray matter changes associated with a disease phenotype (i.e., mood disorder diagnosis), to guide independent postmortem dissection of the identified regional gray matter change for RNA-sequencing studies of gene expression profiles for the disease phenotype in question (i.e., mood disorders). We tested the hypothesis that TF motifs will be associated with differentially expressed genes (DEGs) in the postmortem anterior insula cortex of mood disorder (i.e., MDD and BD) donors relative to controls. These robust imaging-guided transcriptomics methods enabled the goal of realizing a more anatomically precise RNA-seq study of the putative pathological tissue associated with mood disorder diagnoses. The results indicate that relative to controls, DEGs in postmortem mood disorder tissue are associated with TF motifs known to regulate expression of (i)toll-like receptor signaling/immune and inflammatory processing genes, (b) cellular homeostatic control genes, and (c) genes involved in cellular and brain developmental processes.

Methods

Localization of Brain Gray Matter Loss in Mood Disorders

To identify the brain's most anatomically proximate regional involvement in mood pathology, with the goal of targeting the identified pathological sites for postmortem transcriptomics, we first performed a large-scale meta-analysis of voxel-based morphometry studies of gray matter loss in mood disorders using the anatomical likelihood estimation approach. The anatomical likelihood estimation approach models the spatial uncertainty associated with each reported location for significant between-group differences [17], and further compute the convergence across all included experiments by the union of the ensuing probabilistic model relative to a null-distribution and thereby reflecting a random spatial association between the findings of different experiments [18]. The identified brain region exhibiting the most extensive gray matter loss in mood disorder brain imaging cohorts (Fig. 1a) was used for our robust imaging-guided transcriptomics by first generating native space reconstruction of the reduced anatomical subregion(Fig. 1b and c), and then using the reconstructed images was to guide postmortem tissue section in independent samples (Fig. 1c). Specifically, the identified gray matter loss was demarcated in 3D space to guide the dissection of the targeted region in the independent postmortem mood disorder cohorts.

Postmortem Variable Factor Analysis

To explore morbidity-related gene expression profiles beyond the conventional DSM diagnosis-centered case vs. control statistical comparisons, we conducted an exploratory factor analysis, a data reduction technique, to identify higher-order composite variables included with the postmortem data. For each postmortem sample, the donor data includes specific mood disorder and comorbid lifetime-axis I comorbidity (i.e., number of lifetime-axis I diagnostic occurrences, e.g., (poly)-substance use disorders, psychosis, anxiety, eating disorders, alongside the primary mood disorder diagnosis of BD or MDD); comorbid lifetime-axis III diagnoses (i.e., number of lifetime-axis III medical conditions such as diabetes, cancer, cardiovascular disease); cause of death (i.e., death by suicide, homicides, accidents, or natural death due to comorbid axis III medical conditions); and as specified by the medical examiner reports (e.g., blunt force trauma to the chest, gunshot, motor vehicle accident, drowning, hanging); demographics (race, age at death, sex, years of education, number of children/fecundity, and marital records); technical variables (brain-weight, postmortem interval "i.e., the time that has elapsed since a person has died," pH, and RNA integrity number (RIN)); and toxicology (blood alcohol/blood narcotics levels) (see Table 1 for diagnostics relations with demographics, suicide, and other manners of death, positive toxicology, and postmortem qualitative data; and Supplementary Table 1 for diagnostic comorbidity on axis I/co-occurring lifetime mental illness). Principal axis factoring (Oblimin Rotation with Kaizer Normalization) [19] was applied to identify higher-order factors explaining the differences in postmortem variables and included those variables with



Fig. 1 **a**, **b** Gray matter loss in anterior insula cortex of BD and MDD vs. controls as identified with large-scale voxel-based morphometry imaging meta-analysis. **a** Localized anterior insula gray matter reduced area associated with mood disorder diagnoses on a coronal section. **b** The sagittal reconstruction of the reduced volume in (**a**) as well as the 3-dimentional view of the reduced volume. The anatomical information in (**a**) and (**b**) illustrated slide by slide on coronal sections in (**c**) and these images are used to guide postmortem dissection of anterior insula tissue from an independent sample in (**d**)

communalities of ≥ 0.5. Given our focus on identifying TF motifs associated with mood disorder comorbidity burden, we first conducted DEG analysis for bipolar disorder vs. controls, MDD vs. controls, and high vs. low axis I comorbidity by conducting a split-half comparison of the lower half vs. the higher scoring donors on this higher-order variable representing axis I comorbidity.

Brain Dissection The NIMH Human Brain Collection Core (HBCC) provided the *postmortem* samples for which informed consents are acquired according to NIH institutional ethical review board (IRB) guidelines and clinical characterization, neuropathology screening, and toxicology analyses followed previous protocols [20]. In addition, the study received a human subject exemption from the University of Texas at Austin IRB given the anonymized nature of postmortem donor sample data that the research team received from the NIH. We applied *robust imaging-guided transcriptomics* as follows: first, the region of interest targeted for dissection was defined as portion of right AIC encompassing the

Table 1 Anterior insula sample diagnostics, suicide, demographics, toxicology, and *postmortem* quality data

Diagnoses	*N* (No. of females)	Manner of death (No. of females)	Age at death (in mean, SD, and range in years)	Positive toxicology	Postmortem qualitative measures: PMI; Ph; RIN (in mean and range)
Major depressive disorder	30 (11)	24 suicides (10 female suicides), 6 natural (1 female)	47 ± 16.8 (13–75)	Antidepressants = 9 Antipsychotics = 3 Ethanol = 3 Nicotine = 4 Opioids = 4	PMI (28.86; 15–52.5) Ph (6.47; 5.98–6.77) RIN (6.82; 6–7.9)
Bipolar disorder	37 (12)	28 suicides (8 female suicides), 6 natural (3 female), 3 accidental (1 female)	43 ± 14.78; 18–76	Antidepressants = 17 Antipsychotics = 10 Ethanol = 7 Nicotine = 4 Opioids = 8	PMI (31.05; 15–84.5) Ph (6.37; 6–6.86) RIN (6.96; 6–8.2)
Normal controls	33 (10)	0 suicide, 28 natural (9 female), 2 accidental, 3 homicides (1 female)	46 ± 15; 17–74	Antidepressants = 0 Antipsychotics = 0 Ethanol = 2 Nicotine = 6 Opioids = 0	PMI (30.15; 15–60.5) Ph (6.55; 6.25–6.92) RIN (7.37; 6.3–8.3)

MDD, major depressive disorder; *GMV*, gray matter volume; *AIC*, anterior insula cortex; *PMI*, postmortem index; *Ph*, measure of acidity; *RIN*, RNA integrity number which is a measure of RNA quality

identified in a meta-analysis of imaging studies to harbor the most reduced GMV subsection of the entire brain in mood disorders (see Fig. 1a). Electronic image slide of the imaging-defined GMV loss volumes (Fig. 1b and c) was then shared with the HBCC neuropathologist who used these images to guide dissection of coronal tissue slabs of each postmortem donor brain (see Fig. 1d) at the NIH clinical center.

RNA Extraction All dissected tissues were separately pulverized and 50 mg aliquoted from each sample for standardized total RNA processing. Specifically, RNeasy Lipid Tissue Mini Kit (50) was used for RNA purification using the 50 RNeasy Mini Spin Columns, Collection Tubes (1.5 ml and 2 ml), QIAzol Lysis Reagent, RNase-free Reagents, and Buffers kit from Qiagen. DNase treatment was applied to the purified RNA using Qiagen RNase-Free DNase Set (50) kit consisting of 1500 Kunitz units RNase-free DNase I, RNase-free Buffer RDD, and RNase-free water for 50 RNA minipreps. After DNAse treatment, the purified RNA from the pulverized AIC tissue sections were used to determine RNA quality as measured in RNA integrity number (RIN) values using Agilent 6000 RNA Nano Kit consisting of the microfluidic chips, Agilent 6000 RNA Nano ladder, and reagents on Agilent 2100 Bioanalyzer. Samples with RIN < 6 were excluded and the 100 samples meeting inclusion were shipped directly from the NIMH HBCC core to the Genome Sequencing and Analysis Facility (GSAF: https://wikis.utexas.edu/display/GSAF/Home+Page) at the University of Texas, Austin, USA for RNA-sequencing.

Illumina-Sequencing, Read-Mapping, and Gene-Quantification Total RNA was extracted and only samples with RNA integrity numbers (RIN values) greater than 6 as confirmed using the Agilent Bioanalyzer were used for library preparation. First, Ribosomal RNA was depleted using RiboMinus Eukaryote kit from Life Technologies (Foster City, CA, USA) for RNA-seq and confirmed using an Agilent Technologies' Bioanalyzer (Santa Clara, CA, USA). mRNA selection was completed using the Poly(A) purist kit from Thermofisher and paired-end libraries with average insert sizes of 200 bp were obtained using NEBNext Ultra II Directional RNAs Library Prep kit from New England BioLabs. All 100 samples were processed and then sequenced on the Illumina HiSeq 4000, PE150, at the Genome Sequencing and Analysis Facility at UT Austin, USA.

Thirty million paired-end reads per sample (150 base pairs in length) were generated by sequencing runs of 4 samples per lane of the sequencer. Sequenced reads were assessed for quality with Fastqc [21] to specifically assess sequencing reads for median base quality, average base quality, sequence duplication, over-represented sequences, and adapter contamination.

Differential Gene Expression Analysis The reads were pseudo-aligned to the human reference transcriptome (GRCh38- gencode) using kallisto [22], and transcript-level abundances were obtained. The transcript-level counts were aggregated to gene-level using tximport in R. The abundances were normalized using DESeq2 [23, 24] and transformed with variance stabilizing transformation (defined here as a transformation technique that seeks to create more homoscedasticity, thereby having a closer to constant variance in the dataset regardless of the mean expression value [24]).

We performed differential expression analysis based on the negative binomial distribution for modeled gene counts using DESeq2. RIN-values were included in the DESeq2 design matrix as a covariate to control for the potentially confounding effects of RNA quality. The analysis controlled for group factors as well as possible individual outliers by removing genes with expression values of 0 in 80% or more of the samples. We performed differential expression analysis to identify DEGs in the following comparisons: BD vs. controls; MDD vs. controls; and in a pooled cohort of BD and MDD individuals with high vs. low axis I comorbidity and genes with absolute fold change ≥ 2 and adjusted p values ≤ 0.1 were selected as significantly differentially expressed genes. The DESeq2 package by default calculates false discovery rate adjusted p values according to Benjamini and Hochberg [25]. We used an adjusted p value ≤ 0.1 as a cut-off to balance type-1 and type-2 error rates and allow more inclusive capture of regulatory elements/TFs associated with DEGs in for mood disorders across bipolar disorder and unipolar depression.

JASPAR 2018 TF Binding Profiling Given the role of transcription factors (TFs) in regulating gene expression via specific DNA-binding domains (motifs) in the gene promoters, we followed-up on our previous study [26] that identified whole transcriptome gene expression profiles in mood disorders, with the aim to explore in more detail, mood disorder transcriptomics by identifying TF motifs. To this goal, we used JASPAR TF binding database to identify motifs that were associated with DEGs in BD vs. controls; MDD vs. controls; and in pooled mood disorder individuals with high vs. low axis I comorbidity.

JASPAR is an open access database of non-redundant, manually curated TF binding profiles provided as a publicly available web framework [27]. The JASPAR 2018 version has an updated list of 579 non-redundant TF binding profiles of the vertebrate taxonomy that are systematically stored as position frequency matrices (PFMs), which summarizes experimentally determined DNA sequences bound by an individual TFs by counting the number of occurrences of each nucleotide at each position within aligned TF binding sites [27]. This JASPAR 2018 CORE vertebrate database of 579 PFMs was first used to predict TF binding sites in the human genome and then made available to the scientific community through the UCSC Genome Browser track data hub (http://jaspar.genereg.net/genome-tracks/) for use to identify specific TF binding profiles.

EnrichR [28] was used to identify enriched TF gene set motifs that were associated with our DEGs. We focused on the top 10 most significant TF motifs found in the database of 579 PFMs associated with the DEGs observed in our DESeq2 results dataset for each of the 3 analytical contrasts (i.e., BD vs. controls; MDD vs. controls; pooled mood disorder cohort with high axis I comorbidity vs. pooled mood disorder cohort with low axis I comorbidity). TF motifs within the JASPAR 2018 that were found to be associated with DEGs at adjusted p value cutoff of 0.1 (i.e., using the false discovery rate Benjamini and Hochberg multiple comparison method [25] were identified as identified TFs associated with each of the 3 DEG contrasts (i.e., BD vs. controls; MDD vs. controls; low vs. high axis I comorbidity) we selected the top 10 TF motifs (see Figs. 2 and 3).

Results

Robust Imaging-Guided Transcriptomics

Using the anatomical likelihood estimation meta-analysis [17], we previously identified the right anterior insula as the brain region with the most extensive GMV reduction in mood disorders relative to healthy controls (Fig. 1a) [26]. We manually reconstructed this region in ITKSnap (http://www.itksnap.org/pmwiki/pmwiki.php) and provided this 3D volume information to the pathologist at the brain bank to guide postmortem dissection of anterior insula tissue from each sample for subsequent RNA extraction and RNA-sequencing. The dissected regional volume that captured the reduced GMV corresponded to the anterior portion of the insula, where the caudate and putamen are approximately equal in size (Fig. 1a–d).

Postmortem Variability

Factor analysis identified two higher-order factors representing (1) number of axis I diagnostic comorbidity and suicide completion (e.g., substance use disorders or abuse/psychosis/anxiety, and whether the donors died by suicide), and (2) RNA integrity number (RIN) values which were subsequently included in all differential gene expression analyses as covariates. The identified higher-order factor axis I diagnostic comorbidity and suicide completion were used for the comparison of high versus low scores of each of these variables to determine differential gene expression and their regulatory TF motifs.

Apart from race, no other demographic variables differed across groups (MDD and BD samples had more Caucasian donors whereas controls had more African American donors ($p < 0.0001$, $F = 12$)). Covarying for race in subsequent ANOVAs, *axis I comorbidity burden*, which clustered with mood disorder donor sample *suicide completion rate* in the explorative factor analysis, was different across groups ($p < 0.0001$, $F = 30$), showing Bonferroni-corrected pairwise-comparison differences between MDD > controls ($p < 0.0001$); BD > controls ($p < 0.0001$); and BD > MDD ($p = 0.004$).

DEGs and JASPAR TF Motif Identification of Group-Related Differential Gene Expression

We used the JASPAR TF binding database in this study [27]. We found 456 differentially expressed genes for the bipolar vs. controls (Supplementary Table 2) and 2722 differentially expressed genes for MDD vs. controls (Supplementary Table 3). Further analysis that includes DEG results from more than one brain region in the same mood disorder samples will help explain if our observed higher number of DEGs in MDD vs. control samples relative to bipolar disorder vs. controls is pathophysiologically relevant in a region-specific manner. By looking upstream of BD vs. control DEGs for enriched TF motifs, we found that DEGs had motifs of *MIB2*, *Esrrb*, *TEAD2*, *ZBTB7A*, *MIR210*, *MZF1*, *KLF11*, *SMAD4*, *ZNF148*, and *TEAD4* TFs (Fig. 2a). Similar analysis of MDD vs. controls DEGs identified associated motifs of *MIR210*, *TEAD4*, *SP4*, *TEAD2*, *TCFAP2A*, *SP1*, *SP3*, *PCBP1*, *HNF1B*, and *Esrrb* TFs (Fig. 2b).

Given our approach to examine the hierarchical relationship between TF motifs and DEG profiles associated with the degree of psychiatric morbidity/axis I comorbidity in the two mood disorder cohorts, we first used principal axis factoring to identify *axis I comorbidity (i.e., total number of psychiatric diagnoses)*, and *manner of death by suicide or non-suicide* (together comprising the factor we refer to here as the axis I comorbidity burden) to compositely explain variability in (i)*axis I comorbidity burden* and (ii)*suicide completion*. We included this factor in our analysis using a split half approach of high vs. low axis I comorbidity burden to identify TF motifs for DEG profiles for axis I comorbidity burden (see Supplementary Table 4 for complete DEGs). We found DEGs in the pooled BD and MDD donor samples (i.e., without control donors) and these DEGs were associated with TF motifs of *NFATC2*, *GABPA*, *HMAGA1*, *NR3C1*, *GTF2I*, *IRF2*, *POU1F1*, *SAMD9L*, *SNAI1*, and *CBEPB*(Fig. 3). Collectively, these TFs are known to regulate expression of toll-like receptor signaling genes, cellular homeostatic control genes [29], and genes involved in embryonic, cellular, and neurodevelopmental processes.

Specifically, comparing BD vs. controls revealed differentially expressed genes with associated motifs for TFs involved in regulating (a) immune response and antigen processing (i.e. *MIB2*), (b) master transcriptional repression and activation of a wide range of genes (i.e., *ZBTB7A*), (c) Zinc Finger transcriptional control and cellular developmental processes and apoptosis (i.e., *ZBTB7A*, *MZF1*, *KLF11*, *ZNF148*), (d) post-translational modification of gene expression and ion channel transporter expression (i.e., *SMAD4*, *MIR210*, *Esrrb*), and (e)Hippo-signaling pathway, organ size control, and regulation of cell proliferation and apoptosis (i.e., *TEAD2*, *TEAD4*) (Fig. 2a). Comparing MDD vs. controls revealed differentially

Anterior Insula TF Motifs in Mood Disorders vs Controls







Fig. 2 Anterior insula postmortem TF motifs for gene expression profiles in BD and MDD relative to controls. **a** Gene expression profiles in BD vs. controls are illustrated to be associated with the top ten TF motifs for genes that are implicated in regulating inflammatory and immune responses, early embryonic and cellular development, and in posttranscriptional gene expression. **b** Gene expression profiles in MDD vs. controls shown to be associated with the top ten TF motifs known to regulate inflammatory and toll-like receptor signaling, cellular development and peripheral homeostatic/hormonal signaling, and post-transcriptional regulation/DNA methylation. **c** Venn diagram for TF motifs specific for BD vs. controls, MDD vs. controls, and the overlapping TF motifs for which were found for both BD vs. controls and MDD vs. controls

JASPAR TF motifs for High vs. Low Axis-I Comorbidity Load in BD & MDD

NFATC2 (human) → - Promotes induction of interleukin genes IL-2, IL-3, and IL-4 and TNF-alpha transcription during immune response

GABPA (human) → - Activates cytochrome oxidase expression and nuclear control of mitochondrial function
- Regulates expression of adenovirus E4 gene during immune functions

HMGA1 (human) → - Regulates the integration of retroviruses into chromosomes
- Regulates adipogenesis

NR3C1 (human) → - Master regulator of inflammatory and cellular developmental processes
- Regulates glucocorticoid transcription

GTF2I (human) → - Master regulator of general gene expression by interacting with basal transcriptional machinery
- Activates immunoglobulin heavy chain transcription

IRF2 (human) → - Inhibits IRF-mediated transcriptional activation of interferon-alpha and interferon-beta

POU1F1 (human) → - Regulates transcription of genes involved in pituitary development and pituitary hormone expression; with mutations of the TF gene causing pituitary hormone deficiency
- Regulates mammalian cellular and organ development

SAMD9L (human) → - Mediates downregulation of growth-factor signaling by internalizing growth factor receptors

SNAI1 (human) → - Regulates mesoderm formation in developing embryos by transcriptionally repressing and thereby downregulating the expression of ectodermal genes within the mesoderm.
- Regulates cell migration and growth arrest.

CBEPB (human) → - Master regulator of several other transcription factors through transcriptional co-activation
- Controls embryonic development and cell growth

Fig. 3 List of TF genes showing JASPAR 2018 identified associated motifs for gene expression profiles for high compared to low axis I comorbidity burden in BD and MDD. The identified TFs include putative master transcriptional regulators (NR3C1, GTF2I, and CBEPB) as well as regulators of cytokine gene expression (NFATC2 and IRF2), viral mediated functional immune-related gene expression (GABPA and HMGA1), and in regulating early embryonic (SNAI1), cellular (SAMD9L), and hormonal development (POU1F1)

expressed genes with associated motifs for TFs involved in regulating (a) posttranslational modification of gene expression and ion channel transporter expression (i.e., *MIR210*, *Esrrb*) [30] and (b)Hippo-signaling pathway, organ size control, and regulation of cell proliferation and apoptosis (i.e., *TEAD2*, *TEAD4*), (c) Zinc Finger G Protein-Coupled receptor binding TF activity (i.e., *SP4*, *SP3*, *SP1*) implicated in mood disorders [31–33], (d) TF super families involved in embryonic development, activation, or repression of transcriptional activity of different sets of genes and RNA-binding (i.e., *TFAP2A*, *PCBP1*, *HNF1B*) (Fig. 2b).

Restricting our analysis to comparing mood disorder donors with high axis I comorbidity vs. mood disorder donors scoring low on axis I comorbidity, we found differentially expressed genes with associated motifs for TFs involved in regulating (a) inflammatory and immune response and toll-like receptor signaling, (b) embryonic and cellular developmental processes, and (c) cellular and peripheral homeostatic control (see Fig. 3 for specific regulatory functions for each of the identified TFs). When comparing DEGs in high vs. low axis I comorbidity in mood disorders, we found 4 motifs for master TFs implicated in regulation an array of functions including general transcriptional regulation through interaction with basal transcriptional machinery (i.e., *G2FTI*), master transcriptional co-activation of several other TFs (i.e., *CREBBP*), and a master TF that regulates inflammatory, cellular developmental, and glucocorticoid gene expression processes (i.e., *NR3C1* and *POU1F1*) (see Fig. 3 for specific regulatory functions for each of the identified TFs). Specifically, the *GTF2i* TF gene has been genetically associated with the regulation of brain-mediated affective, anxiety and other neurocognitive functions ([34, 35, 36, 37, 38]) and in embryonic and neurodevelopment [38–40]. *CREBBP* has been earlier found to be involved in depressive illness and treatment response [41–43, 44], whereas *POU1F1* [45] and especially *NR3C1* have been implicated in an array of regulatory functions and genetically associated with glucocorticoid functions, and mediating the interplay between early environmental adversity experience and the etiology of mood illnesses [46–55, 56].

Discussion

Understanding the molecular substrates for regional brain abnormalities underlying major mental illness such as mood disorders, which affect over 10% of the population across the lifetime in the USA [14], will not only contribute to better mechanistic understanding of the neurobiological bases for behavioral pathologies [7, 57–59] but will also be essential for novel drug design [1].

In the present study, we applied *robust imaging-guided transcriptomics* to target neuroimaging identified GMV

reductions in the anterior insula associated with mood and depressive disorder diagnoses [9, 26] for dissection and subsequent RNA-seq analysis in postmortem donors. This novel approach allows the precise molecular targeting of a localized anterior insula region that has been found to exhibit the strongest degree of gray matter loss in mood disorders [26]. This *robust imaging-guided transcriptomics* study therefore integrated RNA-seq characterization of gene expression abnormalities in an anatomically abnormal region in mood disorders and allowed testing of the hypothesis that transcription factor motifs will be associated with differential gene expression profiles in the postmortem anterior insula cortex of mood disorder subjects relative to controls.

We found that comparing BD vs. controls revealed DEGs with associated motifs for TFs involved in regulating immune response and antigen processing, master transcriptional repression/activation of a wide range of genes, Zinc Finger transcriptional control of cellular developmental processes, posttranslational modification of gene expression and ion channel transporter expression, and Hippo-signaling pathway involved in organ size control and regulation of cellular development. Comparing MDD vs. controls revealed DEGs with associated motifs for TFs involved in regulating posttranslational modification of gene expression and ion channel transporter expression and Hippo-signaling pathway, Zinc Finger G Protein-Coupled receptor binding TF activity that has been implicated in mood disorders [31–33], and TF super families involved in embryonic and cellular development. DEGs in high vs. low axis I comorbidity revealed motifs for master TFs implicated in the regulation of an array of functions including general transcriptional regulation through interaction with basal transcriptional machinery, and in inflammatory, cellular developmental, and glucocorticoid gene expression processes. Of interest, the two comparisons between BD vs. controls and MDD vs. controls identified TF motifs of similar pathways including four TFs (i.e., *MIR120*, *TEAD2*, *TEAD4*, and *Esrrb*) suggesting possible specific as well as overlapping TF motifs for BD and MDD. If replicated, the identified TF motifs associated with DEGs in mood disorder diagnoses and overall disease morbidity will likely reveal a vulnerability in the general transcriptional pathway mechanism in mood disorder disease states.

The identified DEG profile-associated TF motifs are known to regulate expression of toll-like receptor signaling genes [29], cellular homeostatic control genesb [29], and embryonic and cellular including neurodevelopmental gene networks found to be differentially expressed in BD vs. controls, MDD vs. controls, and in high axis I comorbid mood disorder individuals vs. low axis I comorbidity mood disorder individuals. We found putative hierarchical TF regulatory involvement in the gene expression landscapes associated with BD and MDD diagnoses, such that enrichments of master transcription factors were predominantly associated with the gene expression landscape in elevated mood disorder morbidity, thereby echoing previous work ([4, 6, 1, 2, 60]). It is important to note that a number of the TFs we have associated with anterior insula gene expression in bipolar disorder vs. controls (i.e., MIB2, Esrrb, MZF1, and ZNF148) and in major depressives vs. controls (i.e., PCP1, HNF1B, and Esrrb) are novel in that they have not been previously been identified in any genetic screens. Interestingly, many of the TFs we have identified have been implicated in neural development: TEAD2 and TEAD4 appear to play a role in cortical development [61, 62]. Furthermore, KLF11 [63–66], SP1 [67–72, 73, 74, 75, 76], and SP4 [33, 68, 77] have been found to be involved in the genetic regulation of cell-fate and apoptosis as well as in mood and related psychiatric disorders. And SMAD2 has been linked to antidepressant activity [78] in addition to neuronal development [79]. Finally, our results are in line with recent postmortem studies of other brain areas in mood disorder morbidity that found disease-related gene expression changes in immune and inflammatory signaling [80–85], cellular homeostatic and synaptic signaling [84, 86–93], and in cellular and neurodevelopmental signaling [94].

Conventional analyses of differential gene expression differences related to a specific phenotype of interest do not account for the hierarchical nature of gene expression regulation, e.g., that TFs regulate other gene classes. Our current identification of mood disorder DEG-associated TF motifs known to regulate the expression of toll-like receptor signaling pathway genes, cellular homeostatic control genes, and embryonic, as well as cellular and neurodevelopment pathway genes in mood disorder diagnostic phenotypes, suggests a hierarchical involvement of the identified TFs in the neurobiological abnormalities underlying mood disorder phenotypes.

Despite its obvious strengths, our use of novel *imaging-guided transcriptomics* approach to identify TF motifs associated with gene expression in mood disorders has several limitations. *First*, we provide statistical associations rather than direct testing of the causal role of the identified TF motifs in (1) the developmental or disease-driven emergence of the anatomical gray matter loss identified in the anterior insula of mood disorder individuals, and (2) the observed postmortem differential gene expression landscape measured within the anterior insula in mood disorder morbidity. *Second*, anatomical abnormalities in the anterior insula are not specific to mood disorder diagnoses per se but involved in several neuropsychiatric diagnoses including anxiety, psychosis, substance use, and eating disorders [9, 95], [96]suggesting the importance of including other more mood disorder-specific regional anatomical brain abnormalities in future transcriptomic studies. However, we specifically targeted the anterior insula subsection found to be the most reduced in GMV measures across the entire brain in mood disorders in our meta-analysis with the expectation that this locus of anatomical abnormality likely harbors important transcriptomic clues to mood disorder molecular abnormalities.

Third, our approach does not allow us to confirm whether the postmortem mood disorder samples we examined also showed a reduction in anterior insula GMV. Future studies need to find a way to estimate both anatomical and gene expression abnormalities in the same postmortem brain samples across brain regions to directly link anatomical abnormalities with underlying molecular genetic regulatory abnormalities in the same postmortem brains. *Fourth*, in light of the limited number of samples for a study of complex biological variables, and the fact that the TF data are secondary derivations from the differential gene expression analyses, our results could be confounded by factors between cases and controls, despite our attempts to control for such factors. *Fifth*, bulk tissue RNA-seq cannot account for the role of specific cell-types in defining TF regulatory involvements in mood disorder transcriptomics. Single cell RNA-seq analyses in specific brain regions, ideally across the lifespan, will greatly advance our understanding of the cell-type-specific role of the identified TFs in the pathogenesis of mood disorders. *Finally*, including a comparison psychiatric cohort without mood symptoms such as schizophrenia in future studies will help address the specificity of the identified TF targets for mood disorder therapeutics. These limitations notwithstanding, our current focus on the anterior insula given its identification as the region exhibiting the most extensive gray matter loss associated with mood disorder diagnoses, provide a framework for integrative translational studies of anatomical and molecular abnormalities underlying prevalent brain diseases.

In conclusion, we applied *robust imaging-guided transcriptomics* to characterize the roles of specific TFs in mood disorders. Our study provides important initial insights into the molecular pathways, and the relevant TFs that may be regulating them, in the context of mood disorders and related psychiatric diseases. Our results suggest that the postmortem gene expression patterns we observed in the anterior insula of mood disorder donors are associated with (1) the magnitude of mood disorder morbidity in a putative anatomically compromised brain region in mood disorders; and (2) specific TFs known to regulate broad transcriptional processes, immune response, cellular homeostasis, embryonic and neuronal development, and the etiology of mood disorders. Together, these findings illustrate that studies of gene regulatory networks have the potential to elucidate the hierarchical organizational principles of the gene expression landscapes driving major psychiatric disorders, and thereby accelerate novel pharmacological target discovery.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12035-020-02195-8.

Acknowledgments The NIMH Human Brain Collection Core provided RNA samples for donors and we thank the NIMH and Drs. Barbara Lipska, Stefano Marenco, Pavan Auluck, and HBCC colleagues for the studied samples. We thank Wade Weber of Dell Medical School Psychiatry Department, UT Austin, for assistance in preparing the manuscript, Dr. Mark Bond of Dell Medical School Psychiatry Department, UT Austin, for statistical reviews, and Jessica Podnar and several GSAF colleagues for RNA-seq support.

Author Contributions MJ conceived and designed the studies, and acquired postmortem material from the NIMH HBCC. DA, SBE, and MJ performed the experiments and analyzed the data and results. DA and MJ drafted the manuscript and SBE, CBN, and HH contributed critically and substantially to the content of the manuscript.

Funding This work was supported by the Dell Medical School, UT Austin Mulva Neuroscience Clinics Startup funds for MJ; DA and CBN are supported by the National Institutes of Health (NIH) and HH is supported by NSF.

The funding bodies nor any other entities were involved in the design of the study and collection, analysis, and interpretation of data presented here.

Compliance with Ethical Standards

The NIMH Human Brain Collection Core (HBCC) provided the Postmortem samples for which informed consent was acquired according to NIH institutional ethical review board (IRB) guidelines and clinical characterization, neuropathology screening, and toxicology analyses followed previous protocols [20]. In addition, the study received a human subject exemption from the University of Texas at Austin IRB given the anonymized nature of postmortem donor sample data that the research team received from the NIH.

Conflict of Interest Dhivya Arasappan, none; Simon Eickhoff none; Hans Hofmann, none; Mbemba Jabbi, none.

Charles B Nemeroff:

Research/Grants: National Institutes of Health (NIH)

Consulting (last year): Taisho Pharmaceutical, Inc., Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, Aditum Bio

Stockholder: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness

Scientific Advisory Boards: Brain and Behavior Research Foundation (BBRF), Anxiety Disorders Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS

Board of Directors: Gratitude America, ADAA, Xhale Smart, Inc.

Income sources or equity of $10,000 or more: American Psychiatric Publishing, Xhale, Signant Health, CME Outfitters, Takeda, Intra-Cellular Therapies, Inc., EMA Wellness

Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1)

Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)

Speakers Bureau: None

References

1. Changeux JP (2017) Climbing brain levels of organisation from genes to consciousness. Trends Cogn Sci 21:168–181
2. Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M (2018) The human transcription factors. Cell. 175(2):598–599

3. Kerszberg M, Changeux JP (1998) A simple molecular model of neurulation. Bioessays. 20:758–770
4. Tsigelny IF, Kouznetsova VL, Baitaluk M, Changeux JP (2013) A hierarchical coherent-gene-group model for brain development. Genes Brain Behav 12:147–165
5. Harris RM, Hofmann HA (2014) Neurogenomics of behavioral plasticity. Adv Exp Med Biol 781:149–168
6. Lee TI, Young RA (2013) Transcriptional regulation and its misregulation in disease. Cell. 152(6):1237–51
7. de la Torre-Ubieta L, Stein JL, Won H, Opland CK, Liang D, Lu D et al (2018) The dynamic landscape of open chromatin during human cortical neurogenesis. Cell 172(1-2):289–304.e18
8. Nord AS, Pattabiraman K, Visel A, Rubenstein JLR (2015) Genomic perspectives of transcriptional regulation in forebrain development. Neuron. 85(1):27–47
9. Goodkind M et al (2015) Identification of a common neurobiological substrate for mental Illness. JAMA Psychiatr 72:305–315
10. Wise T et al (2016) Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis. Mol Psychiatry 22:1455–1463
11. McTeague LM, Huemer J, Carreon DM, Jiang Y, Eickhoff SB, Etkin A (2017) Identification of common neural circuit disruptions in cognitive control across psychiatric disorders. Am J Psychiatry 174:676–685
12. McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR (2013) Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 70(8): 821–829
13. Yizhar O (2012) Optogenetic insights into social behavior function. Biol Psychiatry 71:1075–1080
14. Collins PY et al (2011) Grand challenges in global mental health. Nature. 475(7354):27–30
15. Kessler RC et al (2005) Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS- R). Arch Gen Psychiatry 62:617–627
16. Murray CJL et al (2012)Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis of Global Burden of Disease Study 2010. Lancet 380: 2197–2223
17. Eickhoff SB, Laird AR, Grefkes C, Wang LE, Zilles K, Fox PT (2009)Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp 30:2907–2926
18. Eickhoff SB, Bzdok D, Laird AR, Kurth F, Fox PT (2012) Activation likelihood estimation meta-analysis revisited. Neuroimage. 59:2349–2361
19. Costello AB, Osborne JW (2005) Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. Pract Assess Res Eval 10:1–9
20. Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM et al (2006) Critical factors in gene expression in postmortem human brain: focus on studies in schizophrenia. Biol Psychiatry 60(6):650–658
21. Andrews S. (2010). FastQC: a quality control tool for high throughput sequence data; http://www.bioinformatics.babraham.ac.uk/projects/fastqc
22. Bray N, Pimentel H, Melsted P et al (2016)Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34:525–527
23. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11:R106. https://doi.org/10.1186/gb-2010-11-10-r106. https://genomebiology.biomedcentral.com/articles/10.1186/gb-2010-11-10-r106. Accessed 19 Nov 2020
24. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550
25. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57(1):289–300
26. Jabbi M, Arasappan D, Eickhoff SB, Strakowski SM, Nemeroff CB, Hofmann HA (2020)Neuro-transcriptomic signatures for mood disorder morbidity and suicide mortality. J Psychiatr Res 127:62–74
27. Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R (2018) JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res 46:D1284
28. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z et al (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44:W90–W97
29. Akula N, Barb J, Jiang X, Wendland JR, Choi KH, Sen SK, Hou L, Chen DT et al (2014)RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol Psychiatry 19(11):1179–1185
30. Pisanu C, Merkouri Papadima E, Melis C, Congui D, Loizedda A, Orru N, Calza S, Orru S et al (2019) Whole genome expression analyses of miRNAs and mRNAs suggest the involvement of miR-320a and miR-155-3p and their targeted genes in lithium response in bipolar disorder. Int J Mol Sci 20(23):6040
31. Shi J et al (2011)Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 16:193–201
32. Shyn SI et al (2011) Novel loci for major depression identified by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol Psychiatry 16:202–215
33. Zhou X, Tang W, Greenwood TA, Guo S, He L, Geyer MA, Kelsoe JR (2009) Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One 4(4):e5196
34. Jabbi M, Chen Q, Turner N, Kohn P, White M, Kippenhan JS et al (2015) Variation in the Williams syndrome GTF2I gene and anxiety proneness interactively affect prefrontal cortical response to aversive stimuli. Transl Psychiatry 5:e622
35. Procyshyn TL, Spence J, Read S, Watson NV, Crespi BJ (2017) The Williams syndrome prosociality gene GTF2I mediates oxytocin reactivity and social anxiety in a healthy population. Biol Lett. 13(4):20170051
36. Stein MB, Chen CY, Jain S, Jensen KP, He F, Heeringa SG, Kessler RC, Maihofer A, Nock MK, Ripke S, Sun X, Thomas ML, Ursano RJ, Smoller JW, Gelernter J, Army STARRS, Collaborators. (2017) Genetic risk variants for social anxiety. Am J Med Genet B Neuropsychiatr Genet. 174(2):120–131
37. Jabbi M, Kippenhan JS, Kohn P, Marenco S, Mervis CB, Morris CA et al (2012) The Williams syndrome chromosome 7q11.23 hemideletion confers hypersocial, anxious personality coupled with altered insula structure and function. Proc Natl Acad Sci U S A 109: E860–E866
38. Roy AL (2017) Pathophysiology of TFII-I: old guard wearing new hats. Trends Mol Med 23(6):501–511
39. Barak B, Zhang Z, Liu Y, Nir A, Trangle SS, Ennis M, Levandowski KM, Wang D et al (2019) Neuronal deletion of Gtf2i, associated with Williams syndrome, causes behavioral and myelin alterations rescuable by a remyelinating drug. Nat Neurosci 22(5):700–708
40. Enkhmandakh B, Makeyev AV, Erdenechimeg L, Ruddle FH, Chimge NO, Tussie-Luna MI, Roy AL, Bayarsaihan D (2009) Essential functions of the Williams-Beuren syndrome-associated TFII-I genes in embryonic development. Proc Natl Acad Sci U S A 106(1):181–186

41. Cho JH, Irwin MR, Eisenberger NI, Lamkin DM, Cole SW (2019) Transcriptomic predictors of inflammation-induced depressed mood. Neuropsychopharmacology. 44(5):923–929
42. Crisafulli C, Shim DS, Andrisano C, Pae CU, Chiesa A, Han C, Patkar AA, Lee SJ et al (2012)Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Res 198(1):39–46
43. Young LT, Bakish D, Beaulieu S (2002) The neurobiology of treatment response to antidepressants and mood stabilizing medications. J Psychiatry Neurosci 27(4):260–265
44. Fabbri C, Souery D, Calati R, Crisafulli C, Chierchia A, Albani D, Forloni G, Chiesa A et al (2015) Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. J Neural Transm (Vienna) 122(1):43–58
45. Gerritsen L, Milaneschi Y, Vinkers CH, van Hemert AM, van Velzen L, Schmaal L, Penninx BW (2017) HPA axis genes, and their interaction with childhood maltreatment, are related to cortisol levels and stress-related phenotypes. Neuropsychopharmacology. 42(12):2446–2455
46. Duffy A, Goodday SM, Keown-Stoneman C, Scotti M, Maitra M, Nagy C, Horrocks J, Turecki G (2019) Epigenetic markers in inflammation-related genes associated with mood disorder: a cross-sectional and longitudinal study in high-risk offspring of bipolar parents. Int J Bipolar Disord 7(1):17
47. Farrell C, Doolin K, O'Leary N, Jairaj C, Roddy D, Tozzi L, Morris D, Harkin A et al (2018) DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic-pituitary-adrenal axis activity and to early life emotional abuse. Psychiatry Res 265:341–348
48. Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM Jr (2017) Schatzberg AF.HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry 22(4):527–536
49. Kundakovic M, Jaric I (2017) The epigenetic link between prenatal adverse environments and neurodevelopmental disorders. Genes (Basel) 8(3):104
50. Lewis G, Collishaw S, Harold G, Rice F, Thapar A (2012) Maternal depression and child and adolescent depression symptoms: an exploratory test for moderation by CRHR1, FKBP5 and NR3C1 gene variants. Behav Genet 42(1):121–132
51. Mandelli L, Serretti A (2013) Gene environment interaction studies in depression and suicidal behavior: An update. Neurosci Biobehav Rev 37(10 Pt 1):2375–2397
52. Peng H, Zhu Y, Strachan E, Fowler E, Bacus T, Roy-Byrne P, Goldberg J, Vaccarino V et al (2018) Childhood trauma, DNA methylation of stress-related genes, and depression: findings from two monozygotic twin studies. Psychosom Med 80(7):599–608
53. Perroud N, Dayer A, Piguet C, Nallet A, Favre S, Malafosse A, Aubry JM (2014) Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder. Br J Psychiatry 204(1):30–35
54. Roy B, Shelton RC, Dwivedi Y (2017) DNA methylation and expression of stress related genes in PBMC of MDD patients with and without serious suicidal ideation. J Psychiatr Res 89:115–124
55. Smart C, Strathdee G, Watson S, Murgatroyd C, McAllister-Williams RH (2015) Early life trauma, depression and the glucocorticoid receptor gene–an epigenetic perspective. Psychol Med 45(16):3393–3410
56. Kang HJ, Stewart R, Kim JW, Kim SW, Shin IS, Kim MC, Hong YJ, Ahn Y et al (2020) Synergistic effects of depression and NR3C1 methylation on prognosis of acute coronary syndrome. Sci Rep 10(1):5519
57. Jabbi M, Nemeroff CB (2019) Convergent neurobiological predictors of mood and anxiety symptoms and treatment response. Expert Rev Neurother 19:587–597
58. Nestler EJ (2015) Role of the brain's reward circuitry in depression: transcriptional mechanisms. Int Rev Neurobiol 124:151–170
59. Sahin M, Sur M (2015) Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science 350(6263):aab3897
60. Chen C et al (2018) The transcription factor POU3F2 regulates a gene coexpression network in brain tissue from patients with psychiatric disorders. Sci Transl Med 10(472):eaat8178
61. Mukhtar T, Breda J, Grison A, Karimaddini Z, Grobecker P, Iber D, Beisel C, van Nimwegen E et al (2020) Tead transcription factors differentially regulate cortical development. Sci Rep 10(1):4625
62. Wang J, Zhang F, Yang H, Wu H, Cui R, Zhao Y, Jiao C, Wang X et al (2018) Effect of TEAD4 on multilineage differentiation of muscle-derived stem cells. Am J Transl Res 10(3):998–1011
63. Duncan J, Wang N, Zhang X, Johnson S, Harris S, Zheng B, Zhang Q, Rajkowska G et al (2015) Chronic social stress and ethanol increase expression of KLF11, a cell death mediator, in rat brain. Neurotox Res 28(1):18–31
64. Duncan J, Johnson S, Ou XM (2012) Monoamine oxidases in major depressive disorder and alcoholism. Drug Discov Ther 6(3): 112–122
65. Harris S, Johnson S, Duncan JW, Udemgba C, Meyer JH, Albert PR, Lomberk G, Urrutia R et al (2015) Evidence revealing deregulation of the KLF11-MAO A pathway in association with chronic stress and depressive disorders. Neuropsychopharmacology. 40(6): 1373–1382
66. Kollert L, Schiele MA, Thiel C, Menke A, Deckert J, Domschke K (in press) DNA hypomethylation of the Krüppel-like factor 11 (KLF11) gene promoter: a putative biomarker of depression comorbidity in panic disorder and of non-anxious depression? J Neural Transm 2020
67. Brewer S, Feng W, Huang J, Sullivan S, Williams T (2004)Wnt1-Cre-mediated deletion of AP-2alpha causes multiple neural crest-related defects. Dev Biol 267(1):135–152
68. Fusté M, Pinacho R, Meléndez-Pérez I, Villalmanzo N, Villalta-Gil V, Haro JM, Ramos BJ (2013) Reduced expression of SP1 and SP4 transcription factors in peripheral blood mononuclear cells in first-episode psychosis. Psychiatry Res 47(11):1608–1614
69. Hung CY, Hsu TI, Chuang JY, Su TP, Chang WC, Hung JJ (2020) Sp1 in astrocyte is important for neurite outgrowth and synaptogenesis. Mol Neurobiol 57(1):261–277
70. Pinacho R, Villalmanzo N, Lalonde J, Haro JM, Meana JJ, Gill G, Ramos B (2011) The transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium. Bipolar Disord 13(5-6):474–485
71. Saucedo-Uribe E, Genis-Mendoza AD, Diaz-Anzaldua A, Martinez-Magana JJ, Tovilla-Zarate CA, Juarez-Rojop I, Lanzagorta N, Escamilla M et al (2009) Differential effects on neurodevelopment of FTO variants in obesity and bipolar disorder suggested by in silico prediction of functional impact: An analysis in Mexican population. Brain Behav 9(6):3011249
72. Tamayo JM, Sutton VK, Mattei MA, Diaz B, Jamal HH, Vieta E, Zarate CA Jr, Fumero I et al (2009) Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 29(4):358–361
73. Black AR, Jensen D, Lin SY, Azizkhan JC (1999)Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem 274(3):1207–1215
74. Lu W, Ma YY, Shao QQ, Liang J, Qi TT, Huang Y, Wang QJ (2020) ROS/p53/miR3355p/Sp1 axis modulates the migration and epithelial to mesenchymal transition of JEG3 cells. Mol Med Rep 21(3):1208–1216
75. Tapias A, Ciudad CJ, Roninson IB, Noé V (2008) Regulation of Sp1 by cell cycle related proteins. Cell Cycle 7(18):2856–2867

76. Wang YT, Yang WB, Chang WC, Hung JJ (2011) Interplay of posttranslational modifications in Sp1 mediates Sp1 stability during cell cycle progression. J Mol Biol 414(1):1–14
77. Young JW, Kamenski ME, Higa KK, Light GA, Geyer MA, Zhou X (2015)GlyT-1 inhibition attenuates attentional but not learning or motivational deficits of the Sp4 hypomorphic mouse model relevant to psychiatric disorders. Neuropsychopharmacology. 40(12): 2715–2726
78. Dow AL, Russell DS, Duman RS (2005) Regulation of activin mRNA and Smad2 phosphorylation by antidepressant treatment in the rat brain: effects in behavioral models. J Neurosci 25(20): 4908–4916
79. Zhang M, Schöler HR, Greber B (2013) Rapid and efficient generation of neurons from human pluripotent stem cells in a multititre plate format. J Vis Exp 73:e4335
80. Darby MM, Yolken RH, Sabunciyan S (2016) Consistently altered expression of gene sets in postmortem brains of individuals with major psychiatric disorders. Transl Psychiatry 6(9):e890
81. Nagy C, Maitra M, Tanti A, Suderman M, Théroux JF, Davoli MA, Perlman K, Yerko V et al (2020)Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. Nat Neurosci 23(6):771–781
82. Pacifico R, Davis RL (2017) Transcriptome sequencing implicates dorsal striatum-specific gene network, immune response and energy metabolism pathways in bipolar disorder. Mol Psychiatry 22(3): 441–449
83. Pandey GN (2017) Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain. Mod Trends Pharmacopsych 31:79–95
84. Pantazatos SP, Huang YY, Rosoklija GB, Dwork AJ, Arango V, Mann JJ (2007)Whole-transcriptome brain expression and exon-usage profiling in major depression and suicide: evidence for altered glial, endothelial and ATPase activity. Mol Psychiatry 22: 760–773
85. Wohleb ES, Franklin T, Iwata M, Duman RS (2016) Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci 17:497–511
86. Gray AL, Hyde TM, Deep-Soboslay A, Kleinman JE, Sodhi MS (2015) Sex differences in glutamate receptor gene expression in major depression and suicide. Mol Psychiatry 20(9):1057–1068
87. Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P, Lepack A, Majik MS et al (2012) Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 18(9):1413–1417
88. Labonté B et al (2017)Sex-specific transcriptional signatures in human depression. Nat Med 23:1102–1111
89. Li JZ, Bunney BG, Meng F, Hagenauer MH, Walsh DM, Vawter MP, Evans SJ, Choudary PV et al (2013) Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc Natl Acad Sci U S A 110(24):9950–9955
90. Sequeira A, Klempan T, Canetti L, Ffrench-Mullen J, Benkelfat C, Rouleau GA, Turecki G (2007) Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 12:640–655
91. Sequeira A et al (2009) Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 4(8):e6585
92. Yin H, Galfalvy H, Pantazatos SP, Huang YY, Rosoklija GB, Dwork AJ, Burke A, Arango V et al (2016) Glucocorticoid receptor-related genes: genotype and brain gene expression relationships to suicide and major depressive disorder. Depress Anxiety 33(6):531–540
93. Zhao J, Verwer RWH, Gao SF, Qi XR, Lucassen PJ, Kessels HW, Swaab DF (2018) Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide. J Psychiatr Res 102:261–274
94. Paterson C, Wang Y, Hyde TM, Weinberger DR, Kleinman JE, Law AJ (2017) Temporal, diagnostic, and tissue-specific regulation of NRG3 isoform expression in human brain development and affective disorders. Am J Psychiatry 174(3):256–265
95. Janiri D, Moser DA, Doucet GE, Luber MJ, Rasgon A, Lee WH, Murrough JW, Sani G, Eickhoff SB, Frangou S (2019) Shared neural phenotypes for mood and anxiety disorders: a meta-analysis of 226 task-related functional imaging studies. JAMA Psychiatry. 77(2):172–179
96. Craig AD (2009) How do you feel–now? The anterior insula and human awareness. Nat Rev Neurosci 10:59–70

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.